Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer ; volume:16 ; number:1 ; day:16 ; month:2 ; year:2016 ; pages:1-9 ; date:12.2016
BMC cancer ; 16, Heft 1 (16.2.2016), 1-9, 12.2016
- Urheber
-
Uemura, Koichi
- Beteiligte Personen und Organisationen
-
Miyoshi, Yasuhide
Kawahara, Takashi
Yoneyama, Shuko
Hattori, Yusuke
Teranishi, Jun-ichi
Kondô, Keiichi
Moriyama, Masatoshi
Takebayashi, Shigeo
Yokomizo, Yumiko
Yao, Masahiro
Uemura, Hiroji
Noguchi, Kazumi
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2160-1
- URN
-
urn:nbn:de:1111-2016072639935
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Uemura, Koichi
- Miyoshi, Yasuhide
- Kawahara, Takashi
- Yoneyama, Shuko
- Hattori, Yusuke
- Teranishi, Jun-ichi
- Kondô, Keiichi
- Moriyama, Masatoshi
- Takebayashi, Shigeo
- Yokomizo, Yumiko
- Yao, Masahiro
- Uemura, Hiroji
- Noguchi, Kazumi
- SpringerLink (Online service)
Ähnliche Objekte (12)
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer